AUBURN, Wash., March 20, 2019 /PRNewswire/ -- Syntrix Pharmaceuticals today announced the initiation of a Phase 2 study evaluating the efficacy and safety of desmetramadol for the treatment of diabetic neuropathic pain. Desmetramadol promises to provide a critically needed improvement to...
